» Articles » PMID: 1127967

Heparin Therapy During Extracorporeal Circulation. II. The Use of a Dose-response Curve to Individualize Heparin and Protamine Dosage

Overview
Date 1975 May 1
PMID 1127967
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Because the administration of heparin and protamine according to a set protocol will fail to anticoagulate safely or neutralize appropriately a significant number of patients, a method of monitoring heparin therapy during cardiopulmonary bypass is presented. A dose response curve relating heparin dosage to its effect on the activated coagulation time (ACT) can be determined with sufficient accuracy for clinical purposes from three ACT's. Preparation of such a curve makes it possible to maintain anticoagulation in a safe range during bypass and minimizes the number of monitoring tests of coagulation required. At the conclusion of bypass, this curve can be used to predict the precise amount of protamine needed for neutralization. Freed from the confusing effects of hyperheparinemia or protamine excess, the physician can diagnose and treat postoperative bleeding problems much more readily.

Citing Articles

Contributing factors to heparin resistance during cardiopulmonary bypass.

Yamashiro T, Takami Y, Takagi Y J Artif Organs. 2024; 27(4):385-392.

PMID: 38367099 DOI: 10.1007/s10047-024-01435-1.


Comparison of Blood Concentration and Weight-Based Heparin and Protamine Dosing Strategies for Cardiopulmonary Bypass: A Systematic Review and Meta-Analysis.

Raner G, Hu Y, Trowbridge C, Zhang L, Logan J, Wu X Cureus. 2024; 16(2):e54144.

PMID: 38357407 PMC: 10865773. DOI: 10.7759/cureus.54144.


Antithrombin Levels and Heparin Responsiveness during Venoarterial Extracorporeal Membrane Oxygenation: A Prospective Single-center Cohort Study.

Mansour A, Berahou M, Odot J, Pontis A, Parasido A, Reizine F Anesthesiology. 2024; 140(6):1153-1164.

PMID: 38271619 PMC: 11097948. DOI: 10.1097/ALN.0000000000004920.


Evaluation of the use of a heparin dose-response test in dogs to determine the optimal heparin dose during intravascular procedures and assessment of the in vitro heparin response in healthy dogs.

Hellemans A, Devriendt N, Duchateau L, Devreese K, De Somer F, Bosmans T Vet Med Sci. 2023; 10(3):e1326.

PMID: 37987511 PMC: 10951632. DOI: 10.1002/vms3.1326.


Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial.

Trimole R, Manzi H, Hosseini K, Remen T, Toussaint-Hacquard M, Camenzind E Res Pract Thromb Haemost. 2023; 7(2):100083.

PMID: 36915865 PMC: 10005900. DOI: 10.1016/j.rpth.2023.100083.